150
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine

&
Pages 743-747 | Received 18 Apr 2016, Accepted 26 May 2016, Published online: 23 Jun 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Rosamaria Lombardo, Teresa Musumeci, Claudia Carbone & Rosario Pignatello. (2021) Nanotechnologies for intranasal drug delivery: an update of literature. Pharmaceutical Development and Technology 26:8, pages 824-845.
Read now

Articles from other publishers (3)

Guanglu Li, Shaojie Duan, Tiantian Zhu, Zhiying Ren, Hui Xia, Ziyao Wang, Lei Liu & Zunjing Liu. (2023) Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. The Journal of Headache and Pain 24:1.
Crossref
Jenny K.W. Lam, Chucky C.K. Cheung, Michael Y.T. Chow, Emily Harrop, Susie Lapwood, Stephen I.G. Barclay & Ian C.K. Wong. (2020) Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Advanced Drug Delivery Reviews 160, pages 234-243.
Crossref
Gang Zhang, Myles R. McCrary & Ling Wei. 2019. Therapeutic Intranasal Delivery for Stroke and Neurological Disorders. Therapeutic Intranasal Delivery for Stroke and Neurological Disorders 135 147 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.